Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ended December 31, 2021, with the report released on January 28, 2022. The filing serves to furnish the Company's Appendix 4C Quarterly Cashflow Report, as required by Australian Securities Exchange (ASX) regulations, to the U.S. Securities and Exchange Commission.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover sheet referencing an attached exhibit (Exhibit 99.1) containing the detailed quarterly cashflow report, but the numerical data from that exhibit is not included in the provided text.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. It only confirms the submission of the quarterly report required by Australian law.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, specific risks, contingencies, or unusual items. The content is limited to the administrative details of the submission and the signature of the Executive Chairman.
Investor Verification Checklist
- Verify the actual financial figures by reviewing Exhibit 99.1 (Quarterly Report for the Period Ended December 2021), as the summary text contains no data.
- Confirm the company identity is Bionomics Limited, noting the discrepancy with the "Neuphoria Therapeutics Inc." label in the request metadata.
- Check the ASX website for the original Appendix 4C release to ensure the furnished exhibit matches the public record.